Fitness of RECIST 1.1 for non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitor (TKI)

被引:0
|
作者
Sun, Jong-Mu [1 ]
Park, Min Jae [1 ]
Yi, Jun Ho [1 ]
Kong, Jeehyun [1 ]
Kim, Jung-A [1 ]
Lee, Soohyeon [1 ]
Yun, Lin A. [1 ]
Lee, Jeeyun [1 ]
Park, Yeon Hee [1 ]
Ahn, Jin Seok [1 ]
Ahn, Myung-Ju [1 ]
Park, Keunchil [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S716 / S716
页数:1
相关论文
共 50 条
  • [1] Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Park, Min Jae
    Yi, Jun Ho
    Kim, Tae Sung
    Chung, Myung Jin
    Park, Yeon Hee
    Ahn, Jin Seok
    Park, Keunchil
    [J]. LUNG CANCER, 2010, 69 (01) : 105 - 109
  • [2] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [3] Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
    Raez, L. E.
    Baca, Y.
    Nagasaka, M.
    Nieva, J.
    Mandani, H.
    Wanderwalde, A.
    Borghaei, H.
    Naban, C.
    Langer, C.
    Socinsky, M. A.
    Lopes, G.
    Khan, H.
    Wozniak, A.
    Carracedo, C.
    Liu, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S597 - S597
  • [4] Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
    Guttman-Yassky, Emma
    Mita, Alain
    De Jong, Maja
    Matthews, Lesley
    McCarthy, Sean
    Iwata, Kenneth K.
    Verweij, Jaap
    Rowinsky, Eric K.
    Krueger, James G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 2010 - 2019
  • [5] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
    Joshi, Pooja
    Singh, Anita
    Bisht, Dheeraj
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
  • [6] RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
    Nishino, Mizuki
    Cardarella, Stephanie
    Jackman, David M.
    Ramaiya, Nikhil H.
    Rabin, Michael S.
    Hatabu, Hiroto
    Jaenne, Pasi A.
    Johnson, Bruce E.
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2013, 201 (01) : W64 - W71
  • [7] RICTOR signaling modulates the activity of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutated non-small cell lung cancer (NSCLC)
    Fan, Ni
    Zou, Yiyu
    Halmos, Balazs
    Perez-Soler, Roman
    Cheng, Haiying
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [8] Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
    Choi, Hyun Chang
    Kim, Jung Han
    Kim, Hyeong Su
    Jung, Soong Goo
    Hwang, Sang Muk
    Ju, Sung Bae
    Yang, Ik
    [J]. JOURNAL OF CANCER, 2015, 6 (07): : 652 - 657
  • [9] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors
    Benesova, Lucie
    Minarik, Marek
    Jancarikova, Dana
    Belsanova, Barbora
    Pesek, Milos
    [J]. ANTICANCER RESEARCH, 2010, 30 (05) : 1667 - 1671
  • [10] Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)